Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights

Get insights on Senores Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Senores Pharmaceuticals Ltd Share Price Chart

Senores Pharmaceuticals Ltd Fundamentals

Traded Volume: 1,55,019

Market Cap(Cr): 3,774

Avg Traded Price 820.69

1 Year return %

Upper Circuit 831

Lower Circuit 812

P/E TTM 43.00

P/B Ratio 19.00

Traded Value(Cr) 1270.46

EPS TTM 18.917

Book value 18.917

Dividend 0.00%

Senores Pharmaceuticals Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Senores Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Senores Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +3.39%

1M +12.31%

3M +15.13%

1Y null%

YTD +44.54%

Senores Pharmaceuticals Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Senores Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 4.25L

Day Before Yesterday 1.87L

1W Avg 2.33L

1M Avg 3.89L

3M Avg 3.01L

Senores Pharmaceuticals Ltd Technical Details

Senores Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 811

Support 2 802

Support 3 792

Pivot Point : 821

Resistance 1 830

Resistance 2 840

Resistance 3 849

Senores Pharmaceuticals Ltd Corporate Actions

Senores Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Senores Pharmaceuticals Ltd’s capital allocation strategies.

All

Dividends

No Dividend has been declared by SENORES

Bonus

No Bonus has been declared by SENORES

Splits

No Split has been declared by SENORES

Others

Rights No Rights has been declared by SENORES

Senores Pharmaceuticals Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Senores Pharmaceuticals Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Senores Pharmaceuticals Ltd's relative performance and valuation against major competitors.

Stock Name Orchid Pharma Ltd ₹866.40 (-0.38%) M. Cap (Cr) 43.94 1 Yr Return (%) -41.36% P/E (TTM) 84.09 PB Ratio 3.59

Stock Name Innova Captab Ltd ₹759.45 (+3.73%) M. Cap (Cr) 43.46 1 Yr Return (%) -21.61% P/E (TTM) 34.92 PB Ratio 4.53

Stock Name Aarti Drugs Ltd ₹442.10 (-1.05%) M. Cap (Cr) 40.64 1 Yr Return (%) -2.78% P/E (TTM) 20.27 PB Ratio 3.16

Stock Name Senores Pharmaceuticals Ltd ₹819.55 (-0.75%) M. Cap (Cr) 37.74 1 Yr Return (%) NaN% P/E (TTM) 43.32 PB Ratio 4.80

Stock Name Dishman Carbogen Amcis Ltd ₹237.95 (-3.33%) M. Cap (Cr) 37.31 1 Yr Return (%) +8.89% P/E (TTM) 27.35 PB Ratio 0.65

Stock Name RPG Life Sciences Ltd ₹2254.00 (+1.30%) M. Cap (Cr) 37.28 1 Yr Return (%) +10.91% P/E (TTM) 17.31 PB Ratio 9.83

Stock Name Gufic BioSciences Ltd ₹352.45 (+2.86%) M. Cap (Cr) 35.34 1 Yr Return (%) -13.10% P/E (TTM) 62.10 PB Ratio 6.16

Senores Pharmaceuticals Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Senores Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 -20.40 Mar 2024 -62.82 Mar 2023 -43.41 Mar 2022 -12.20 Mar 2021 -2.87

PARTICULARS Investing Activities Mar 2025 -162.94 Mar 2024 -13.51 Mar 2023 -5.23 Mar 2022 -11.26 Mar 2021 -4.37

PARTICULARS Financing Activities Mar 2025 532.62 Mar 2024 86.68 Mar 2023 47.08 Mar 2022 23.36 Mar 2021 8.50

PARTICULARS Net Cash Flow Mar 2025 349.28 Mar 2024 10.35 Mar 2023 -1.57 Mar 2022 -0.10 Mar 2021 1.25

Senores Pharmaceuticals Ltd Shareholding Pattern

This shows the ownership breakdown of Senores Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 45.8%

Public 41.3%

Other Institutions 5.08%

FII 4.28%

Mutual Funds 3.54%

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as Senores Pharmaceuticals Private Limited through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022.The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024. The Company launched the IPO of 14,887,723 Equity Shares of face value Rs 10 each, by raising money aggregating to Rs 582.11 Crore, comprising a fresh issue of 12,787,723 equity shares amounting to Rs 500 Crore and the offer for sale of 2,100,000 equity shares amounting to Rs 82.11 Cr in December, 2024.The Company has commenced manufacturing activities at its greenfield API plant located in Gujarat in FY 2025.

Managing Director

SWAPNIL JATINBHAI SHAH

Registered office #.1101-1103 11th Flr South Twr, Ambali Bopal Road, Ahmedabad, Gujarat, 380054

FAX :+91-79-2999 9857

Background

Incorporation Year 2017

Face Value ₹10.00

Market Lot 1

Senores Pharmaceuticals Ltd Latest News

VIEW MORE NEWS

FAQs on Senores Pharmaceuticals Ltd